Expression of regulatory T cells and natural killer T cells in peripheral blood of children with Wilms tumor
CHEN Jing, LIN Tao
Department of Urology, Children's Hospital of Chongqing Medical University;Pediatric Research Institute of Children's Hospital of Chongqing Medical University;Chongqing Key Laboratory of Pediatrics;Ministry of Education Key Laboratory of Child Development and Disorders;China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China
Abstract Objective To study the changes and clinical significance of CD4+CD25+CD127low regulatory T cells (Treg) and CD3+CD16+CD56+ natural killer T cells (NKT) in peripheral blood of children with Wilms tumor. Methods Twenty-one children with Wilms tumor were enrolled as the case group, and twenty-one healthy children for physical examinations were enrolled as the control group. Flow cytometry was used to detect the levels of CD4+CD25+CD127low T cells and CD3+CD16+CD56+ T cells in peripheral blood of two groups. Results The level of Treg cells in peripheral blood of the case group was significantly lower than in the control group (P < 0.05). The level of NKT cells in peripheral blood of the case group was significantly higher than in the control group (P < 0.05). Conclusions Treg cells and NKT cells play important roles in the occurrence and development of Wilms tumor. Treg cells and NKT cells may be useful indexes for evaluating immunological function in children with Wilms tumor.
CHEN Jing,LIN Tao. Expression of regulatory T cells and natural killer T cells in peripheral blood of children with Wilms tumor[J]. CJCP, 2016, 18(12): 1222-1226.
CHEN Jing,LIN Tao. Expression of regulatory T cells and natural killer T cells in peripheral blood of children with Wilms tumor[J]. CJCP, 2016, 18(12): 1222-1226.
Pastore G, Znaor A, Spreafico F, et al. Malignant renal tumours incidence and survival in European children (1978-1997):report from the Automated Childhood Cancer Information System project[J]. Eur J Cancer, 2006, 42(13):2103-2114.
[2]
Lin YC, Mahalingam J, Chiang JM, et al. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer[J]. Int J Cancer, 2013, 132(6):1341-1350.
[3]
Bendelac A, Savage PB, Teyton L. The biology of NKT cells[J]. Annu Rev Immunol, 2007, 25:297-336.
[4]
Rijavec M, Volarevic S, Osolnik K, et al. Natural killer T cells in pulmonary disorders[J]. Respir Med, 2011, 105 Suppl 1:S20-S25.
[5]
Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system[J]. Nat Rev Immunol, 2010, 10(7):490-500.
[6]
Allan SE, Passerini L, Bacchetta R, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs[J]. J Clin Invest, 2005, 115(11):3276-3284.
[7]
Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain(CD127), allowing consistent identification and sorting of live cells[J]. J Immunol Methods, 2007, 319(1-2):41-52.
[8]
Joshi SK, Lang ML. Fine tuning a well-oiled machine:Influence of NK1.1 and NKG2D on NKT cell development and function[J]. Int Immunopharmacol, 2013, 17(2):260-266.
[9]
Das R, Tripathy A. Increased expressions of NKp44, NKp46 on NK/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection[J]. Med Microbiol Immunol, 2014, 203(5):303-314.
[10]
Gibson SE, Swerdlow SH, Felgar RE. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features[J]. Hum Pathol, 2011, 42(5):679-687.
[11]
Hus I, Staroslawska E, Bojarska-junak A, et al. CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma[J]. Folia Histochem Cytobiol, 2011, 49(1):183-187.
[12]
Schreiber TH, Wolf D, Bodero M, et al. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination[J]. Oncoimmunology, 2012, 1(5):642-648.
[13]
Reduta T, Stasiak-Barmuta A, Laudańska H. CD4+CD25+ and CD4+CD25high regulatory T cells in disseminated and localized forms of allergic contact dermatitis:relation to specific cytokines[J]. Folia Histochem Cytobiol, 2011, 49(2):255-262.
[14]
Exley MA, Lynch L, Varghese B, et al. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer:reversing tumor-induced defects[J]. Clinical Immunol, 2011, 140(2):184-195.
[15]
Obata F, Subrahmanyam PB, Vozenilek AE, et al. Natural killer T (NKT) cells accelerate Shiga toxin type 2(Stx2) pathology in mice[J]. Front Microbiol, 2014, 6:262.
[16]
Tan JQ, Xiao W, Wang L, et al. Type I natural killer T cells:naturally born for fighting[J]. Acta Pharmacol Sin, 2010, 31(9):1123-1132.
[17]
Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions[J]. Nat Rev Immunol, 2013, 13(2):101-117.
Nguyen KD, Vanichsarn C, Nadeau KC. Increased cytotoxicity of CD4+ invariant NKT cells against CD4+CD25hiCD127lo- regulatory T cells in allergic asthma[J]. Eur J Immunol, 2008, 38(7):2034-2045.
[21]
Terabe M, Berzofsky JA. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases[J]. Cancer Immunol Immunother, 2014, 63(3):199-213.
